 SALT LAKE CITY, July 21, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American College of Medical Genetics and Genomics ACMG, advising that genetic carrier screening be offered to all people who are pregnant or considering a pregnancy. The statement recommends screening for more than 110 genetic disorders regardless of family history or ethnicity. ACMG previously recommended more limited carrier screening and for only certain ethnicities. 